子宮頸癌治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Cervical Cancer Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月12日 | 出版商:

Global Market Insights Inc. | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計從 2024 年到 2032 年，子宮頸癌治療市場規模將以 5.3% 的複合年成長率擴大，這主要是由研究機構、製藥公司和醫療保健提供者之間不斷加強的合作推動的。隨著研究人員深入研究免疫療法和標靶治療等旨在提高患者治療效果的創新療法，這些合作夥伴關係至關重要。這種合作促進了資源共享和專業知識交流，加速了新藥和療法的發展。例如，2024 年 1 月，美國國家癌症研究所 (NCI) 與公共和私人實體合作，啟動了臨床試驗網路。該計劃旨在收集有關「自我收集」HPV 檢測方法的資料，提高子宮頸癌篩檢的可近性。

整個市場分為癌症類型、產品、配銷通路和地區。

根據癌症類型，從 2024 年到 2032 年，腺癌領域的子宮頸癌治療市場價值預計將大幅成長。研究人員正在積極研究標靶療法，以解決與腺癌相關的獨特突變和細胞行為。此外，免疫療法正在研究中，在增強人體對這種癌症類型的免疫反應方面顯示出有希望的早期結果。

預計到 2032 年，線上藥局配銷通路領域的子宮頸癌治療產業價值將以複合年成長率大幅成長。線上平台正在擴大服務範圍，確保偏遠或服務欠缺地區的患者能夠及時獲得治療。此外，這些藥局正在利用先進的物流和技術，改善其交付流程，以提高效率和可靠性。

從區域來看，亞太地區子宮頸癌治療市場規模預計將在 2024 年至 2032 年間強勁成長。各國正在對公共衛生運動和篩檢計畫進行投資，旨在提高意識並倡導早期發現。此外，我們也非常注重研發，以創新治療為目標。投資也用於加強醫療基礎設施，確保該地區更廣泛地獲得這些療法。

產業生態系統分析
產業影響力
- 成長動力
  - 全球子宮頸癌盛行率上升
  - 政府不斷採取措施來傳播疾病意識
  - HPV 感染發生率上升
  - 增加癌症研究的研發經費
- 產業陷阱與挑戰
  - 與治療相關的不良反應
  - 治療費用高
成長潛力分析
監管環境
技術景觀
- 核心技術
- 鄰近技術
未來市場趨勢
差距分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按癌症類型，2021 - 2032 年

主要趨勢
鱗狀細胞癌
腺癌
腺鱗癌

第 6 章：市場估計與預測：按產品分類，2021 - 2032 年

主要趨勢
預防
- 加衛苗/加衛苗9
- 子宮頸癌
治療
- 阿瓦斯丁
- 可瑞達
- 泛型
- 其他治療

第 7 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

AbbVie Inc.
AstraZeneca PLC
Biocon Limited
Mylan N.V.
Bristol-Myers Squibb Company
Eli Lilly And Company
F. Hoffmann-La Roche Ltd
Fresenius SE and Co. KGaA
GSK plc
Hikma Pharmaceuticals PLC
Mckesson Corporation
Merck and Co., Inc.
Pfizer Inc.
Sandoz Group AG
Xiamen Wantai Canghai Biotechnology Co., Ltd.

簡介目錄

Product Code: 10222

Cervical Cancer Treatment Market size is projected to expand at a 5.3% CAGR from 2024 to 2032, primarily driven by increasing collaborations among research institutions, pharmaceutical companies, and healthcare providers. These partnerships are pivotal as researchers delve into innovative therapies, such as immunotherapies and targeted treatments, aiming to enhance patient outcomes. Such collaborations facilitate resource sharing and expertise exchange, accelerating the development of novel drugs and therapies. For example, in January 2024, the National Cancer Institute (NCI), in partnership with both public and private entities, inaugurated a clinical trial network. This initiative aims to collect data on a "self-collection" HPV testing method, enhancing accessibility to cervical cancer screenings.

The overall market is segregated into cancer type, product, distribution channel, and region.

Based on cancer type, the cervical cancer treatment market value from the adenocarcinoma segment is estimated to rise at a significant rate from 2024 to 2032. This surge is attributed to the rising emphasis on enhancing survival rates and the overall quality of life for patients. Researchers are actively investigating targeted therapies to tackle the unique mutations and cellular behaviors linked to adenocarcinoma. Furthermore, immunotherapies are under study, showing promising early results in amplifying the body's immune response against this cancer type.

Cervical cancer treatment industry value from the online pharmacies distribution channel segment is anticipated to expand at a substantial CAGR up to 2032. This is largely due to the escalating demand for easier medication access for patients. Online platforms are broadening their services, ensuring timely treatment access for patients in remote or underserved regions. Moreover, these pharmacies are harnessing advanced logistics and technology, refining their delivery processes for enhanced efficiency and reliability.

Regionally, the Asia Pacific cervical cancer treatment market size is projected to depict robust growth between 2024 and 2032. This momentum is fueled by escalating government initiatives and funding. Countries are channeling investments into public health campaigns and screening programs, aiming to elevate awareness and champion early detection. Moreover, there is a pronounced focus on R and D, targeting innovative treatments. Investments are also directed towards bolstering healthcare infrastructure, ensuring broader access to these therapies in the region.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of cervical cancer globally
  - 3.2.1.2 Growing government initiatives to spread disease awareness
  - 3.2.1.3 Rising incidence of HPV infections
  - 3.2.1.4 Increase in R and D funding for cancer research
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Adverse effects associated with the treatment
  - 3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Gap analysis
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Squamous cell carcinoma
5.3 Adenocarcinoma
5.4 Adenosquamous carcinoma

Chapter 6 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Prevention
- 6.2.1 Gardasil/gardasil9
- 6.2.2 Cervarix
6.3 Treatment
- 6.3.1 Avastin
- 6.3.2 Keytruda
- 6.3.3 Generics
- 6.3.4 Other treatments

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa